# Gitlab Inc.: financial statements, quarterly

GTLB · Nasdaq · CIK 1653482 · [Technology](/sectors/technology.md) · fiscal year ends Jan 31

Pages: [Overview](/companies/gtlb.md) · [Financials](/companies/gtlb/financials.md) · [Filings](/companies/gtlb/filings.md) · [Insiders](/companies/gtlb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/gtlb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [150](/filings/0001628280-24-050129.md) | [164 d](/filings/0001628280-26-018731.md) | [169](/filings/0001628280-25-030546.md) | [183](/filings/0001653482-25-000010.md) | [196](/filings/0001628280-25-054840.md) | [211 d](/filings/0001628280-26-018731.md) | [215](/filings/0001628280-26-039793.md) | [236](/filings/0001628280-26-059943.md) | [244](/filings/0001628280-25-054840.md) | [260 d](/filings/0001628280-26-018731.md) | [264](/filings/0001628280-26-039793.md) | [286](/filings/0001628280-26-059943.md) |
| Cost of revenue | $m | [15.1](/filings/0001628280-24-050129.md) | [16.0 d](/filings/0001628280-26-018731.md) | [18.8](/filings/0001628280-25-030546.md) | [21.4](/filings/0001653482-25-000010.md) | [22.1](/filings/0001628280-25-054840.md) | [22.9 d](/filings/0001628280-26-018731.md) | [25.0](/filings/0001628280-26-039793.md) | [28.5](/filings/0001628280-26-059943.md) | [32.2](/filings/0001628280-25-054840.md) | [35.0 d](/filings/0001628280-26-018731.md) | [37.5](/filings/0001628280-26-039793.md) | [45.6](/filings/0001628280-26-059943.md) |
| Gross profit | $m | [135](/filings/0001628280-24-050129.md) | [148 d](/filings/0001628280-26-018731.md) | [150](/filings/0001628280-25-030546.md) | [161](/filings/0001653482-25-000010.md) | [174](/filings/0001628280-25-054840.md) | [189 d](/filings/0001628280-26-018731.md) | [189](/filings/0001628280-26-039793.md) | [207](/filings/0001628280-26-059943.md) | [212](/filings/0001628280-25-054840.md) | [225 d](/filings/0001628280-26-018731.md) | [227](/filings/0001628280-26-039793.md) | [241](/filings/0001628280-26-059943.md) |
| Research and development | $m | [49.1](/filings/0001628280-24-050129.md) | [52.4 d](/filings/0001628280-26-018731.md) | [54.1](/filings/0001628280-25-030546.md) | [61.3](/filings/0001653482-25-000010.md) | [61.4](/filings/0001628280-25-054840.md) | [62.9 d](/filings/0001628280-26-018731.md) | [65.4](/filings/0001628280-26-039793.md) | [71.5](/filings/0001628280-26-059943.md) | [68.7](/filings/0001628280-25-054840.md) | [69.0 d](/filings/0001628280-26-018731.md) | [71.5](/filings/0001628280-26-039793.md) | [95.0](/filings/0001628280-26-059943.md) |
| Operating income | $m | [(40.3)](/filings/0001628280-24-050129.md) | [(34.9) d](/filings/0001628280-26-018731.md) | [(53.6)](/filings/0001628280-25-030546.md) | [(41.0)](/filings/0001653482-25-000010.md) | [(28.7)](/filings/0001628280-25-054840.md) | [(19.3) d](/filings/0001628280-26-018731.md) | [(34.6)](/filings/0001628280-26-039793.md) | [(18.4)](/filings/0001628280-26-059943.md) | [(12.4)](/filings/0001628280-25-054840.md) | [(5.2) d](/filings/0001628280-26-018731.md) | [(15.7)](/filings/0001628280-26-039793.md) | [(56.9)](/filings/0001628280-26-059943.md) |
| Income tax | $m | [257](/filings/0001628280-24-050129.md) | [2.9 d](/filings/0001628280-26-018731.md) | [13.0](/filings/0001628280-25-030546.md) | [(39.2)](/filings/0001653482-25-000010.md) | [(39.2)](/filings/0001628280-25-054840.md) | [(11.3) d](/filings/0001628280-26-018731.md) | [2.5](/filings/0001628280-26-039793.md) | [2.2](/filings/0001628280-26-059943.md) | [1.8](/filings/0001628280-25-054840.md) | [3.9 d](/filings/0001628280-26-018731.md) | [2.0](/filings/0001628280-26-039793.md) | [(3.2)](/filings/0001628280-26-059943.md) |
| Net income | $m | [(285)](/filings/0001628280-24-050129.md) | [(38.0) d](/filings/0001628280-26-018731.md) | [(55.2)](/filings/0001628280-25-030546.md) | [12.9](/filings/0001653482-25-000010.md) | [29.1](/filings/0001628280-25-054840.md) | [6.9 d](/filings/0001628280-26-018731.md) | [(35.9)](/filings/0001628280-26-039793.md) | [(9.2)](/filings/0001628280-26-059943.md) | [(8.3)](/filings/0001628280-25-054840.md) | [(2.6) d](/filings/0001628280-26-018731.md) | [(5.0)](/filings/0001628280-26-039793.md) | [(36.8)](/filings/0001628280-26-059943.md) |
| Diluted EPS | $ per share | [(1.84)](/filings/0001628280-24-050129.md) | not reported | [(0.35)](/filings/0001628280-25-030546.md) | [0.08](/filings/0001653482-25-000010.md) | [0.17](/filings/0001628280-25-054840.md) | not reported | [(0.22)](/filings/0001628280-26-039793.md) | [(0.06)](/filings/0001628280-26-059943.md) | [(0.05)](/filings/0001628280-25-054840.md) | not reported | [(0.03)](/filings/0001628280-26-039793.md) | [(0.22)](/filings/0001628280-26-059943.md) |
| Basic EPS | $ per share | [(1.84)](/filings/0001628280-24-050129.md) | not reported | [(0.35)](/filings/0001628280-25-030546.md) | [0.08](/filings/0001653482-25-000010.md) | [0.18](/filings/0001628280-25-054840.md) | not reported | [(0.22)](/filings/0001628280-26-039793.md) | [(0.06)](/filings/0001628280-26-059943.md) | [(0.05)](/filings/0001628280-25-054840.md) | not reported | [(0.03)](/filings/0001628280-26-039793.md) | [(0.22)](/filings/0001628280-26-059943.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2024 (2023-10-31) | FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [285](/filings/0001628280-23-040671.md) | [288](/filings/0001628280-25-014344.md) | [420](/filings/0001628280-24-026458.md) | [439](/filings/0001628280-24-039196.md) | [177](/filings/0001628280-24-050129.md) | [228](/filings/0001628280-26-018731.md) | [256](/filings/0001628280-25-030546.md) | [261](/filings/0001653482-25-000010.md) | [224](/filings/0001628280-25-054840.md) | [230](/filings/0001628280-26-059943.md) | [335](/filings/0001628280-26-039793.md) | [226](/filings/0001628280-26-059943.md) |
| Current assets | $m | [1,182](/filings/0001628280-23-040671.md) | [1,284](/filings/0001628280-25-014344.md) | [1,263](/filings/0001628280-24-026458.md) | [1,314](/filings/0001628280-24-039196.md) | [1,192](/filings/0001628280-24-050129.md) | [1,336](/filings/0001628280-26-018731.md) | [1,381](/filings/0001628280-25-030546.md) | [1,436](/filings/0001653482-25-000010.md) | [1,507](/filings/0001628280-25-054840.md) | [1,656](/filings/0001628280-26-059943.md) | [1,639](/filings/0001628280-26-039793.md) | [1,595](/filings/0001628280-26-059943.md) |
| Total assets | $m | [1,227](/filings/0001628280-23-040671.md) | [1,321](/filings/0001628280-25-014344.md) | [1,322](/filings/0001628280-24-026458.md) | [1,376](/filings/0001628280-24-039196.md) | [1,253](/filings/0001628280-24-050129.md) | [1,399](/filings/0001628280-26-018731.md) | [1,442](/filings/0001628280-25-030546.md) | [1,498](/filings/0001653482-25-000010.md) | [1,571](/filings/0001628280-25-054840.md) | [1,723](/filings/0001628280-26-059943.md) | [1,706](/filings/0001628280-26-039793.md) | [1,662](/filings/0001628280-26-059943.md) |
| Current liabilities | $m | [586](/filings/0001628280-23-040671.md) | [677](/filings/0001628280-25-014344.md) | [675](/filings/0001628280-24-026458.md) | [667](/filings/0001628280-24-039196.md) | [465](/filings/0001628280-24-050129.md) | [545](/filings/0001628280-26-018731.md) | [556](/filings/0001628280-25-030546.md) | [553](/filings/0001653482-25-000010.md) | [566](/filings/0001628280-25-054840.md) | [652](/filings/0001628280-26-059943.md) | [643](/filings/0001628280-26-039793.md) | [662](/filings/0001628280-26-059943.md) |
| Total liabilities | $m | [634](/filings/0001628280-23-040671.md) | [715](/filings/0001628280-25-014344.md) | [707](/filings/0001628280-24-026458.md) | [688](/filings/0001628280-24-039196.md) | [482](/filings/0001628280-24-050129.md) | [578](/filings/0001628280-26-018731.md) | [589](/filings/0001628280-25-030546.md) | [587](/filings/0001653482-25-000010.md) | [603](/filings/0001628280-25-054840.md) | [686](/filings/0001628280-26-059943.md) | [674](/filings/0001628280-26-039793.md) | [690](/filings/0001628280-26-059943.md) |
| Shareholders' equity | $m | [547](/filings/0001628280-23-040671.md) | [560](/filings/0001628280-25-014344.md) | [568](/filings/0001628280-24-026458.md) | [643](/filings/0001628280-24-039196.md) | [725](/filings/0001628280-24-050129.md) | [776](/filings/0001628280-26-018731.md) | [808](/filings/0001628280-25-030546.md) | [867](/filings/0001653482-25-000010.md) | [923](/filings/0001628280-25-054840.md) | [991](/filings/0001628280-26-059943.md) | [985](/filings/0001628280-26-039793.md) | [926](/filings/0001628280-26-059943.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(6.0) d](/filings/0001628280-24-050129.md) | [24.9 d](/filings/0001628280-26-018731.md) | [38.1](/filings/0001628280-25-030546.md) | [11.7 d](/filings/0001653482-25-000010.md) | [(177) d](/filings/0001628280-25-054840.md) | [63.2 d](/filings/0001628280-26-018731.md) | [106](/filings/0001628280-26-039793.md) | [49.4 d](/filings/0001628280-26-059943.md) | [31.4 d](/filings/0001628280-25-054840.md) | [45.8 d](/filings/0001628280-26-018731.md) | [149](/filings/0001628280-26-039793.md) | [(3.1) d](/filings/0001628280-26-059943.md) |
| Capital expenditure | $m | [0.7 d](/filings/0001628280-24-050129.md) | [0.3 d](/filings/0001628280-26-018731.md) | [0.7](/filings/0001628280-25-030546.md) | [0.9 d](/filings/0001653482-25-000010.md) | [1.1 d](/filings/0001628280-25-054840.md) | [1.2 d](/filings/0001628280-26-018731.md) | [0.9](/filings/0001628280-26-039793.md) | [2.9 d](/filings/0001628280-26-059943.md) | [3.0 d](/filings/0001628280-25-054840.md) | [4.0 d](/filings/0001628280-26-018731.md) | [2.4](/filings/0001628280-26-039793.md) | [0.2 d](/filings/0001628280-26-059943.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001628280-26-039793.md) | [0.0 d](/filings/0001628280-26-059943.md) | not reported | not reported | [50.0](/filings/0001628280-26-039793.md) | [105 d](/filings/0001628280-26-059943.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2023 (2022-10-31) | Q1 FY2024 (2023-04-30) | Q2 FY2024 (2023-07-31) | Q3 FY2024 (2023-10-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [149](/filings/0001628280-23-040671.md) | [152](/filings/0001628280-24-026458.md) | [154](/filings/0001628280-24-039196.md) | [155](/filings/0001628280-24-050129.md) | [158](/filings/0001628280-25-030546.md) | [166](/filings/0001653482-25-000010.md) | [167](/filings/0001628280-25-054840.md) | [164](/filings/0001628280-26-039793.md) | [166](/filings/0001628280-26-059943.md) | [167](/filings/0001628280-25-054840.md) | [170](/filings/0001628280-26-039793.md) | [169](/filings/0001628280-26-059943.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.